Investor Relations

Webcast ImageWebcast
Q3 2016 C. R. Bard, Inc. Earnings Conference Call (Live)
10/25/16 at 5:00 p.m. ET
Q3 2016 C. R. Bard, Inc. Earnings Conference Call
Tuesday, October 25, 2016 5:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download DocumentationQ2 2016 Earnings Presentation
Download DocumentationAnalyst Meeting Presentation
BCR (Common Stock)
ExchangeNYSE (US Dollar)
Change (%) Stock is Down 0.81 (0.37%)
Data as of 10/21/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Reports
Download Documentation2016 Proxy Statement
Download Documentation2015 Annual Report
Related Links
Corporate Governance
Contact the Bard Board of Directors
Recent NewsMore >>
10/12/16Bard Declares Quarterly Dividend
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 12, 2016-- The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today declared a regular quarterly dividend of 26 cents per share on Bard's common stock. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on November 4, 2016 to shareholders of record at the close of business on October 24, 2016. C. R. Bard, Inc. (, headquartered in Murray Hill, NJ,... 
Printer Friendly Version
10/03/16Bard to Host Earnings Conference Call on October 25, 2016
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 3, 2016-- C. R. Bard, Inc. (NYSE: BCR) today announced that it will host a conference call on Tuesday, October 25, 2016 at 5:00 PM EDT, to discuss the company’s third quarter 2016 operating results, and to provide financial guidance for the fourth quarter of 2016. Bard is scheduled to issue an earnings press release after the market closes on October 25, 2016. A live audio webcast of Bard's investor... 
Printer Friendly Version
09/22/16LUTONIX® Global Real-World Registry 24-Month Outcomes Presented at VIVA 2016
MURRAY HILL, N.J.--(BUSINESS WIRE)--Sep. 22, 2016-- C. R. Bard, Inc. (NYSE:BCR) announced the presentation of the final 24-month results from the LUTONIX® Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 Meeting. These results are the first reported final 24-month outcomes for “real-word” registry data for Drug Coated Balloon PTA Catheters (DCBs). The registry includes a subgroup of patients with long femoropopliteal lesions (... 
Printer Friendly Version
09/19/16FDA Approves 6-Month Primary End Point for the Lutonix® Below-the-Knee Drug Coated Balloon
MURRAY HILL, N.J.--(BUSINESS WIRE)--Sep. 19, 2016-- C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a 6-month time point for the Lutonix® 014 Drug Coated Balloon PTA Catheter (DCB). The Lutonix® 014 device is currently the only DCB in an IDE clinical trial in the U.S. for treatment of arteries below ... 
Printer Friendly Version
Selected SEC Filings
Filing DateForm
07/27/1610-Q Download SEC Filing to Adobe PDF Download XBRL Content
04/28/1610-Q Download SEC Filing to Adobe PDF Download XBRL Content
02/12/1610-K Download SEC Filing to Adobe PDF Download XBRL Content
10/23/1510-Q Download SEC Filing to Adobe PDF Download XBRL Content
07/24/1510-Q Download SEC Filing to Adobe PDF Download XBRL Content
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever C. R. Bard, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.